Similar articles

• Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.

  Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1994 May;13(5):597-611. Bone Marrow Transplant. 1994. PMID: 8054913
• Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.

  Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1996 Mar;17(3):305-8. Bone Marrow Transplant. 1996. PMID: 8704678
• Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.

  Waldmann H, Hale G, Cobbold S. Waldmann H, et al. Philos Trans R Soc Lond B Biol Sci. 2001 May 29;356(1409):659-63. doi: 10.1098/rstb.2001.0841. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11375069 Free PMC article. Review.
• CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.

  Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H. Hale G, et al. Bone Marrow Transplant. 2000 Jul;26(1):69-76. doi: 10.1038/sj.bmt.1702477. Bone Marrow Transplant. 2000. PMID: 10918407
• The use of monoclonal antibodies in allogeneic bone marrow transplantation.

  Fischer A. Fischer A. Br J Haematol. 1993 Apr;83(4):531-4. doi: 10.1111/j.1365-2141.1993.tb04686.x. Br J Haematol. 1993. PMID: 8518171 Review. No abstract available.